The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma.
 
Yoshitaka Narita
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Nihon Medi-Physics; Novocure; Ono Pharmaceutical; SERVIER; Sumitomo Dainippon Pharma Oncology
Consulting or Advisory Role - SERVIER; Sumitomo Pharma Oncology; SymBio Pharmaceuticals
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Incyte Japan (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); novocure (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PPD Global (Inst); Sumitomo Pharma Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Makoto Ohno
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Novocure (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PPD Global (Inst); Sumitomo Pharma Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Shota Tanaka
Honoraria - Baxter; Daiichi Sankyo; Eisai; Goryo Chemical; Integra LifeSciences; Japan Organ Transplant Network; Nxera Pharma Co., Ltd; Ono Pharmaceutical; Otsuka
Research Funding - Eisai (Inst); Momotaro Gene Inc. (Inst); Novocure (Inst); Takeda Science Foundation (Inst)
 
Yukihiko Sonoda
Honoraria - Bristol-Myers Squibb; CSL Behring; Daiichi Sankyo; Integra LifeSciences; Johnson & Johnson; Medtronic; Novocure; Nxera Pharma; Ono Pharmaceutical; Otsuka; Pfizer
Research Funding - Chugai Pharma (Inst); Otsuka (Inst); PDR pharma (Inst)
 
Kazuhiko Mishima
Honoraria - Eisai; Novocure; Ohara Pharmaceutical; Ono Pharmaceutical
Research Funding - CSL Behring (Inst); Eisai (Inst); Gunze (Inst); Kyowa Kirin (Inst); Nihon Medi-Physics (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); S & Brain (Inst); Stryker (Inst); Taiho Pharmaceutical (Inst)
 
Eiichi Ishikawa
Honoraria - Amgen; Chugai Pharma; Daiichi Sankyo; Eisai; Otsuka; Tsumura & Co.
Consulting or Advisory Role - Epsilon Imaging
 
Ken Ohashi
Honoraria - AstraZeneca Japan; Merck; Novo Nordisk; Ono Pharmaceutical; Sanofi; Sumitomo Pharma Oncology
 
Motoo Nagane
Honoraria - Eisai; Kyowa Kirin International; Nippon Kayaku; Ohara Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan; Nippon Shinyaku; Ohara Pharmaceutical; Ono Pharmaceutical; SERVIER
Speakers' Bureau - Nihon Medi-Physics; Novocure; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma; Daiichi Sankyo/UCB Japan (Inst); HOYA Techonosurgical (Inst); Johnson & Johnson/Janssen (Inst); Kyowa Kirin International; Nippon Kayaku; Ono Pharmaceutical; Saney Seiko (Inst); TERUMO
Travel, Accommodations, Expenses - Daiichi Sankyo/UCB Japan; Denka Co., Ltd; Eisai; Kyowa Kirin International; Nippon Kayaku; Novocure; Ohara Pharmaceutical; Ono Pharmaceutical; SERVIER
 
Chifumi Kitanaka
Patents, Royalties, Other Intellectual Property - Nobelpharma